Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Learn how global experts are leveraging the latest data on antibody&ndash drug conjugates targeting HER2 HER3 and TROP2 to optimally manage patients with NSCLC! Download slides watch the on-demand Webcast and listen to a podcast adapted from the live expert Webinar on new developments from ELCC 2021 then review the most important data on lung cancer from ASCO 2021.

Share

Program Content

No activities added yet

Activities

ADCs in NSCLC
Novel ADCs for Treatment of NSCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 08, 2021

Expires: April 07, 2022

Activity of ADCs in NSCLC
Activity of ADCs in Clinical Trials for Lung Cancer: Anti-HER2/HER3 ADCs
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 08, 2021

Expires: April 07, 2022

TROP-2/CEACAM/c-MET ADCs
Activity of ADCs in Clinical Trials for Lung Cancer: Anti–TROP-2/CEACAM/c-Met ADCs
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 08, 2021

Expires: April 07, 2022

<i>Express Points</i>: ADCs in NSCLC Post-ELCC
Express Points
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 14, 2021

Expires: April 13, 2022

Activities

ADCs in NSCLC Post-ELCC
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: May 18, 2021

Expires: May 17, 2022

Activities

ADCs in NSCLC: Which Pts
My Thoughts on When to Consider ADCs for Today’s Patients With Advanced NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 20, 2021

Expires: April 19, 2022

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.